Cost-Effectiveness of Pharmacist-Provided Treatment of Adult Pharyngitis
April 13, 2012
Donald G. Klepser, PhD, MBA; Sara E. Bisanz, PharmD; and Michael E. Klepser, PharmD
There are over 12 million ambulatory care visits for acute pharyngitis annually in the United States.1 Approximately 15% to 30% of these cases are attributable to group A streptococcus (GAS) in children, and 5% to 10% in adults.2 Treatment of pharyngitis caused by GAS, or strep throat, has traditionally been initiated in the setting of a clinic and performed by a physician or mid-level practitioner. Protocols for the treatment of GAS pharyngitis are available, but there is some debate over which approach is optimal. The current guidelines from the Infectious Diseases Society of America recommend that adults be diagnosed through culture or rapid antigen detection test (RADT) if the physician cannot confidently exclude the diagnosis of GAS on epidemiological or clinical grounds. The Infectious Diseases Society of America guidelines do not recommend confirmation of a negative RADT test with culture in adults.3 In actual practice, physicians are likely to use a variety of strategies when diagnosing and managing GAS pharyngitis. These include observation with no testing or treatment, empiric treatment of all patients with suspected GAS pharyngitis, testing with culture alone, testing with RADT alone, and testing with RADT with a follow-up culture for negative results.
In recent years, pharmacists in the community setting have taken on more diversified roles as frontline healthcare providers. Examples of these expanded roles include providing vaccinations, offering travel medicine services, managing anticoagulation clinics, and identifying and treating patients with influenza. Another possible expansion of pharmacist services would be the diagnosis and treatment of GAS pharyngitis. While the pharmacist could never replace the physician in the diagnosis and treatment of complex patients, it is possible that pharmacists could provide a cost-effective treatment alternative for disease states such as GAS pharyngitis. For diseases such as GAS pharyngitis, use of a pharmacist- as-provider care model might yield cost savings through reduced provider expenses and improved access to care resulting in fewer missed days of school and/or work and containment of disease.
Few data evaluating pharmacist-provided care for GAS have been published. A study from 1978 concluded that cost savings could be realized through pharmacist management of streptococcal throat infections; however, this study was relatively small and not reflective of contemporary practice.4 In 2002 the National Community Pharmacists Association, in collaboration with US Wellness Inc, implemented a program to train pharmacists to conduct rapid strep testing in the community pharmacy and charge for this service.5 The status of this initiative is unknown, but testing for GAS is not yet a common practice in community pharmacies. Additional studies have evaluated the cost associated with the management of GAS, but these do not consider the possibility of pharmacist-provided care.6,7
This research will provide the first cost-effectiveness evaluation of a pharmacist-as-provider program for the diagnosis and treatment of GAS pharyngitis as compared with standard of care provided by physicians and nurse practitioners.
In order to evaluate the cost-effectiveness of pharmacistprovided care for GAS pharyngitis, a decision model was constructed. This model was largely based on the decision model used in the Neuner study, which consisted of 5 arms designed to determine the best method of treatment of pharyngitis in a physician’s office.6 As with the Neuner model, patients included in this model were adults presenting with acute pharyngitis. High-risk patients, such as the immunocompromised, were not included in our model since those patients generally require additional follow-up to monitor their therapy. Our final treatment model consisted of 7 arms: 1) physician observation only; 2) physician treatment of all patients empirically with antibiotics; 3) physician performing a throat culture on all patients; 4) physician performing an RADT on all patients, and performing a throat culture on those with a negative RADT result; 5) physician performing only an RADT; 6) a nurse practitioner in a walk-in clinic performing an RADT on all patients; 7) a pharmacist performing an RADT on all patients in a community pharmacy setting. The first 5 arms are identical to those of the Neuner study. The nurse practitioner arm was added to assess the effect of a recent rise in urgent care clinics, which are often staffed by nurse practitioners. Although the Neuner study concluded that culturing all patients is the most cost-effective method of diagnosis and management of patients with pharyngitis, we elected to include all 5 arms in our model because this allowed us to compare a pharmacy-based treatment model with various medical practices, not simply what is considered the ideal.
Possible complications of GAS were considered in building the decision tree. These complications included acute rheumatic fever (ARF), peritonsillar abscess, and allergic reaction to penicillin. Other complications reported in the literature but not included in our model include glomerulonephritis, otitis media, and sinusitis. A recent Cochrane review described the effect of antibiotics in preventing glomerulonephritis, otitis media, and sinusitis as compared with placebo.8 For these complications, the difference between the rate of complications with and without antibiotics was determined not to be clinically significant and left the authors to speculate if GAS truly causes these complications or if they are simply associated with one another.
The decision tree model was constructed and analyzed using the TreeAge Pro Suite 2009 version 1.0.2. The Figure represents the pharmacy arm of the tree. The entire tree can be seen in Appendices A-H.
As with the Neuner model, certain assumptions were made. First, patients were assumed to have no history of ARF or a penicillin allergy. Screening for high-risk patients was assumed to be 100% effective in all settings. Patients developing ARF were assumed to develop no other complication. Patient adherence to therapy is assumed to be 100%. A willingness-to-pay parameter of $137 per quality-adjusted life-day (QALD) was used. This number was based on the common standard of a willingness-to-pay of $50,000 per quality-adjusted life-year (QALY), which was then divided by 365 days in the year.
Our model assumes that the visits in all arms include similar procedures with the exception of the previously described differences in treatment strategy. This includes a basic physical examination of the respiratory system and neck, the collection of vital signs, and detailed written record of the encounter.
It was assumed that pharmacists would be able to carry out the physical assessment and RADT testing with same effectiveness as a physician or a nurse practitioner. It was surmised that pharmacists would be able to dispense antibiotics to the appropriate patients at the pharmacy immediately after RADT testing. This could be possible through a collaborative practice agreement set up with a physician, similar to how collaborative practice agreements are set up for the administration of vaccines in the community pharmacy setting. Finally, it is assumed that there is no cost associated with the establishment of a collaborative practice agreement.
The costs and probabilities used in the model are described in Table 1. The probabilities used in our study were largely those used in the Neuner study as well as in the Cochrane review.6,8 The original sources of the probabilities were reviewed to verify the quality of the information. The authors of the Neuner study averaged the results of several studies to determine the sensitivity and specificity of the RADT test. We used these averaged values, along with the prevalence of GAS, to calculate the following probabilities: RADT positive test result, true positive, true negative, false positive, and false negative.
Cost information was taken from several sources. The cost of penicillin and treatment of the adverse events of penicillin- induced rash, anaphylaxis, peritonsillar abscess, and acute rheumatic fever were taken from the Neuner study.6 Since these values were given in US dollars from 2000, it was necessary to update these costs to reflect the effect of inflation. From April 2000 to April 2010, the healthcare inflation rate was 1.5, meaning that $1.00 in 2000 would have the same purchasing power as $1.50 in 2010.15 Therefore, the cost of penicillin and the cost of treatment of adverse effects from the Neuner article were multiplied by 1.5 to reflect current costs. The cost of a physician visit was based on the 2010 physician fee schedule from the Centers for Medicare & Medicaid Services (CMS) using a Healthcare Common Procedure Coding System (HCPCS) code of 99213, which allows 15 minutes of face-to-face time with the patient and/or family.16 Cost for a walk-in clinic was also calculated using the CMS physician fee schedule based on the fact that a nurse practitioner is reimbursed at a rate of 85% of a physician.17 Pharmacist reimbursement was based on reimbursement rates for provision of medication therapy management (MTM) services, which are currently billable services to Medicare.18,19 CMS reimbursement rates for a throat culture and RADT were also used.14 A Current Procedural Terminology (CPT) code of 87880QW was used for the RADT, and a CPT code of 87070 was used for the culture. One should note that practitioner time is considered a separate cost from testing. For example, if a patient went into a walk-in clinic and received an RADT test, the cost would be $55.80 (practitioner time) + $17.18 (cost of test).
Utility information was the same as what was used in the Neuner study, which was given in lost QALDs. A utility of 0.95 per day was assigned to pharyngitis, which is the utility associated with other minor symptoms such as diarrhea and dyspepsia.20 Therefore, the QALDs lost with pharyngitis are based on the duration of symptoms. Untreated pharyngitis is associated with symptom duration of 5 days for a total QALD loss of 0.25. Similarly, pharyngitis treated after culture diagnosis is associated with a symptom duration of 4 days due to the delay in initiating therapy, and pharyngitis treated empirically or after RADT is associated with a symptom duration of 3 days. The Neuner study assigned utilities to anaphylaxis, penicillin-induced rash, and ARF based on a patient survey,21 and assigned utility to peritonsillar abscess based on a previous decision analysis that used expert opionion.12
Using our baseline probabilities, costs, and utilities, treatment of GAS pharyngitis by a pharmacist was the most costeffective treatment strategy (measured in dollars/QALDs gained). Pharmacist treatment dominated all of the other methods except physician culture and physician RADT with follow-up culture (Table 2). The incremental cost-effectiveness ratio (ICER) for physician culture was $6042 per QALD gained and $40,745 for physician RADT with followup culture. Both values greatly exceed the $137 per QALD threshold.
As seen in Table 2, the QALDs lost with all of the treatments were quite comparable, with the exception of empirical treatment by a physician. There is a difference of 0.0096 QALDs between physician culture and physician observation. Since the differences among strategies were negligible, this indicated that all treatments (excluding physician empirical therapy) are equally effective. Therefore, a cost-minimization approach may be taken in analyzing the data rather than a cost-effectiveness approach, choosing the treatment method with the lowest overall cost.
A one-way sensitivity analysis was performed on all probability and cost variables using a cost-minimization strategy. The variable for RADT negative GAS positive (false negative) probability was the only variable that changed the study results in the sensitivity analysis.
RADT Negative GAS Positive. This is the probability that an RADT test result will be negative, but that the patient will still be GAS positive. At a false negative probability of >0.22, physician observation is the cost-minimizing option at $80.40 followed by physician culture at a false negative probability of >0.24 and a cost of $82.30.
Pharmacist Cost. A threshold analysis was conducted to see at what point pharmacist-provided care is not the most cost-minimizing option. At a pharmacist cost of $55.56, walkin clinics become the cost-minimizing option.
Of the 7 strategies studied, pharmacist-provided care was the most cost-effective strategy as well as the cost-minimizing strategy for the diagnosis and treatment of GAS pharyngitis in adults. Only the rate of false negatives affected the results in a sensitivity analysis for the cost-minimization strategy. The results change at a false negative rate >0.22, which is considerably higher than the baseline false negative rate of 0.013. The probability of a false negative can be calculated by subtracting the true positive rate from the GAS prevalence, and the true positive rate is calculated by multiplying the sensitivity by the GAS prevalence. Therefore, the false negative probability can be raised by either raising the GAS prevalence or lowering the sensitivity. If sensitivity is lowered and GAS prevalence is kept at baseline, the false negative rate is 0.033. If the sensitivity is kept at baseline and the GAS prevalence is raised, the false negative rate becomes 0.21. Therefore, both variables need to be adjusted concurrently to achieve a false negative >0.22. Because of the unlikelihood of achieving a false negative probability as high as 0.22, we are confident in the robustness of our conclusion that pharmacists are the most cost-minimizing option.
Whether or not patients would accept pharmacists as the healthcare provider for diagnosis and treatment of GAS pharyngitis is unknown. A pharmacy-based service that could serve as an indicator to answer this question is immunization. Prior to 1996, only 9 states allowed pharmacists to give immunizations.22 As of June 2009, all 50 states allow pharmacists to be immunizers.23 This rapid growth of pharmacy- based immunization seems to indicate that patients are willing to accept pharmacists as providers of low-complexity medical care.
A challenge for the implementation of pharmacy-based diagnosis and treatment of GAS pharyngitis is the development of a procedure for incorporating testing into the normal pharmacy work flow. Unlike immunizations, GAS testing cannot be scheduled for certain days or times of day. Rather, patients requesting testing must be helped as they come in. A recommended procedure for handling these patients is as follows: 1) screen out and refer to physicians high-risk patients such as pregnant women or the immunocompromised; 2) collect a history of the current illness from patient; 3) conduct physical examination of respiratory system and neck and collect vital signs; 4) perform RADT test; 5) bill for testing services; 6) prescribe antibiotics for those testing positive based on a treatment protocol; 7) dispense antibiotics for those testing positive, and recommend over-the-counter therapy for those testing negative; 8) produce detailed written record of encounter to be shared with primary care physician. All patients should be encouraged to follow up with their primary care physician if symptoms worsen or do not improve within 48 to 72 hours.
Another challenge for the implementation of pharmacybased treatment for GAS pharyngitis is the lack of ability of pharmacists to bill for these cognitive services. The RADT test itself can be billed through its existing CPT code. However, pharmacists cannot currently bill for the time to provide such a service, as such a CPT/HCPCS code does not exist. It is conceivable that a code could be added, though, based on the addition of an HCPCS code for the provision of MTM services with the passage of Medicare part D.
The current research is based on a number of assumptions that allow pharmacists to provide GAS pharyngitis treatment. In particular, states may require that pharmacists obtain additional training and/or credentialing prior to performing this service. The requirements will vary by state and may impact the ability of pharmacists to conduct the service as described.
Future research needs to look at how implementing pharmacist-based GAS pharyngitis treatment fits into a pharmacy business model. Performing GAS testing would
take time away from the more traditional dispensing function. It would only make sense from a business perspective to implement this new service if the profit made from performing GAS testing were equal to or greater than the profit gained from dispensing prescriptions within that same amount of time. We know from the threshold analysis that pharmacists are the most cost-minimizing option, at a cost below $55.56, so the maximum fee charged by a pharmacy to test for GAS would be $72.74 ($55.56 for pharmacist cost and $17.18 for RADT test cost). In determining the profitability of GAS testing, one also needs to consider the costs associated with additional training and credentialing and setting up a collaborative practice agreement. Neither of these costs nor the profits gained from filling prescriptions to treat GAS pharyngitis were considered in this decision model. Finally, since this study only evaluates the adult population, future research needs to evaluate the pediatric population. This may be especially important since GAS prevalence is higher in the pediatric population than the adult population.
The role of pharmacists in the healthcare system is constantly evolving. Recent publications highlighting the role of community-based pharmacists as frontline healthcare providers and gatekeepers to the healthcare system have demonstrated an intriguing new role for pharmacists. Identifying and treating patients early in the course of their disease has several potential benefits to patients, society, and the healthcare system. Since pharmacists are highly accessible and have established practice sites, they offer the potential to impact the course of many diseases in a highly cost-effective manner. More studies need to be conducted demonstrating the clinical and economic value of pharmacists practicing in this manner.1. Halsey ES. Bacterial pharyngitis. Medscape Reference WebMD website.http://emedicine.medscape.com/article/225243-overview. Updated 2009. Accessed April 9, 2010.
2. Schroeder BM. Diagnosis and management of group A streptococcal pharyngitis. Am Fam Physician. 2003;67(4):880, 883-884.
3. Bisno AL, Gerber MA, Gwaltney JM Jr, Kaplan EL, Schwartz RH; Infectious Diseases Society of America. Practice guidelines for the diagnosis and management of group A streptococcal pharyngitis. Clin Infect Dis. 2002;35(2):113-125.
4. Davis S. Evaluation of pharmacist management of streptococcal throat infections in a health maintenance organization. Am J Hosp Pharm. 1978; 35(5):561-566.
5. Ukens C. Strep tests added to R.Ph. care lineup. Drug Topics. 2002; 146(1):23. http://search.ebscohost.com/login.aspx?direct=true&db=heh &AN=6113686&login.asp&site=ehost-live.
6. Neuner JM, Hamel MB, Phillips RS, Bona K, Aronson MD. Diagnosis and management of adults with pharyngitis: a cost-effectiveness analysis. Ann Intern Med. 2003;139(2):113-122.
7. Pfoh E, Wessels MR, Goldmann D, Lee GM. Burden and economic cost of group A streptococcal pharyngitis. Pediatrics. 2008;121(2): 229-234.
8. Del Mar CB, Glasziou PP, Spinks AB. Antibiotics for sore throat. Cochrane Database Syst Rev. 2006;(4)(4):CD000023.
9. Komaroff AL, Pass TM, Aronson MD, et al. The prediction of streptococcal pharyngitis in adults. J Gen Intern Med. 1986;1(1):1-7.
10. deShazo RD, Kemp SF. Allergic reactions to drugs and biologic agents. JAMA. 1997;278(22):1895-1906.
11. Sandord JP. Management of pharyngitis in an era of declining incidence of rheumatic fever: an overview and synthesis. In: Shulman ST, ed. Pharyngitis: Management in an Era of Declining Rheumatic Fever. 1984:251-254.
12. Hillner BE, Centor RM. What a difference a day makes: a decision analysis of adult streptococcal pharyngitis. J Gen Intern Med. 1987;2(4): 244-250.
13. Feinstein AR, Harrison FW, Spagnuolo M, et al. Rheumatic fever in children and adolescents: a long-term epidemiologic study of subsequent prophylaxis, streptococcal infections, and clinical sequelae. Ann Intern Med. 1964(60):87.
14. Clinical Laboratory Fee Schedule. Centers for Medicare & Medicaid Services website. http://www.cms.gov/ClinicalLabFeeSched/02_clinlab.asp#TopOfPage. Accessed June 10, 2010.
15. Consumer Price Index—All Urban Consumers. Bureau of Labor Statistics website. http://data.bls.gov/cgi-bin/surveymost?cu. Updated 2010. Accessed June 18, 2010.
16. Physician fee schedule look-up. Centers for Medicare & Medicaid Services website. http://www.cms.gov/PfsLookup/. Updated 2010. Accessed June 18, 2010.
17. Buppert C. Billing for nurse practitioner services: guidelines for NPs, physicians, employers, and insurers. Medscape, WebMD website.http://www.mc.vanderbilt.edu/documents/CAPNAH/files/Mentoring/Section%204/Billing%20for%20Nurse%20Practitioner%20svcs_%20Guidelines%20for%20NPs%20Phys%20Employers%20and%20Insurers.pdf. Accessed June 10, 2010.
18. Mirixa. Tennesse Pharmacists Association website. http://www.tnpharm.org/MTM/MirixaPharmacyFAQwithcomments.pdf. Accessed June 11, 2010.
19. OneCare-HMO Medication Therapy Management (MTM) Program/Medicine Review Program. CalOptima website. http://www.caloptima.org/en/Providers/ManualsPoliciesAndResources/OneCareHMOSNPProviderManual.aspx. Accessed June 12, 2010.
20. Tengs TO, Wallace A. One thousand health-related quality-of-life estimates. Med Care. 2000;38(6):583-637.
21. Herman JM. Patients’ willingness to take risks in the management of pharyngitis. J Fam Pract. 1984;19(6):767-772.
22. Steyer TE, Ragucci KR, Pearson WS, Mainous AG 3rd. The role of pharmacists in the delivery of influenza vaccinations. Vaccine. 2004;22(8): 1001-1006.
23. States where pharmacists can immunize. American Pharmacists Association website. http://www.pharmacist.com/AM/Template.cfm? Section=Home2&CONTENTID=21623&TEMPLATE=/CM/ContentDisplay.cfm. Accessed June 10, 2010.Author Affiliations: From University of Nebraska Medical Center (DGK, SB), Omaha, NE; Ferris State University (MEK), Kalamazoo, MI.
Funding Source: There was no external funding source for this study.
Author Disclosures: The authors (DGK, SEB, MEK) report no relationship or financial interest with any entity that would pose a conflict of interest with the subject matter of this article.
Authorship Information: Concept and design (DGK, SEB, MEK); acquisition of data (DGK, SEB); analysis and interpretation of data (DGK, SEB); drafting of the manuscript (DGK, SEB, MEK); critical revision of the manuscript for important intellectual content (MEK); statistical analysis (DGK, SEB); and supervision (DGK).
Address correspondence to: Donald G. Klepser, PhD, MBA, 986045 Nebraska Medical Center, Omaha, NE. E-mail: email@example.com.